BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Galena Biopharma  

310 N. State Street, Suite 208

Lake Oswego   Oregon  97034  U.S.A.
Phone: 1-503-400-7636 Fax: 1-503-400-6611


SEARCH JOBS




Industry
Pharmaceutical






 Company News
Galena Biopharma  (GALE) Presents HER2 Screening Data Including Preliminary Leica Bond Oracle™ Results From the Phase 3 NeuVax™ (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS) 12/11/2014 7:45:28 AM
Galena Biopharma  (GALE) Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th American Society of Hematology Annual Meeting & Exposition 12/8/2014 8:27:46 AM
Galena Biopharma  (GALE) To Present HER2 Screening Data From The Phase 3 Neuvax™ (Nelipepimut-S) Clinical Trial At The 2014 San Antonio Breast Cancer Symposium (SABCS) 12/8/2014 7:26:26 AM
Galena Biopharma  (GALE) Receives Notice Of Allowance Of U.S. Patent Application For GALE-401 (Anagrelide Controlled Release) Composition Of Matter 12/2/2014 11:54:44 AM
Galena Biopharma  (GALE) To Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data At The 56th American Society of Hematology Annual Meeting & Exposition 12/1/2014 9:40:33 AM
Galena Biopharma  (GALE) To Present At The Oppenheimer 25th Annual Healthcare Conference 11/25/2014 11:40:03 AM
Lincoln Park Doubles Down On Oncology With $55M Galena Biopharma  (GALE) Bet 11/21/2014 6:21:04 AM
Galena Biopharma  (GALE) Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 11/18/2014 11:55:00 AM
Galena Biopharma  (GALE) To Present At The Stifel 2014 Healthcare Conference 11/13/2014 10:38:11 AM
Galena Biopharma  (GALE) Doses First Patient In Phase 2 Clinical Trial With Neuvax(TM) (Nelipepimut-S) In Combination With Herceptin® (Trastuzumab) To Treat High-Risk HER2 3+ Or HER2 Gene-Amplified Breast Cancer Patients 11/11/2014 7:18:24 AM
12345678910...